Lea James is an associate working in the litigation department of Foley & Lardner LLP. Lea is based in the firm’s Boston office where she is a member of the Business Litigation & Dispute Resolution Practice.
Lea served as a summer associate in the firm’s Milwaukee office in both 2017 and 2018.
Prior to joining Foley, Lea served as a research assistant to Professor Owen Jones at Vanderbilt University Law School and assisted in drafting the new edition of the textbook Law and Neuroscience. Before pursuing her legal career, Lea worked for a contract research organization doing preclinical and clinical research involving pharmaceuticals and medical devices, a role in which she worked with both pharmaceutical companies and the FDA.
Presentations and Publications
- Co-author, “Cancer Drugs: Antibody-Drug Conjugate Litigation,” Foley Insights (August 13, 2024)
- Co-author, “Members of Congress Call for DOJ to Investigate Possible Antitrust Violations in Oil Industry,” Foley Insights (June 18, 2024)
- Author, “Pharming Out Data: A Proposal for Promoting Innovation and Public Health through a Hybrid Clinical Data Protection Scheme,” Vanderbilt Journal of Transnational Law (November 2018)
- Co-author, “When a Promise Isn’t Enough—Crafting Proper Employee Patent Assignments,” JD Supra (December 2018)
Understanding the Risk vs. Reward of Department of Justice’s Corporate Criminal Whistleblower Awards Pilot
The Securities & Exchange Commission, the Department of Health & Human Services, and other agencies have long had established bounty programs that reward successful tipsters.
Cancer Drugs: Antibody-Drug Conjugate Litigation
The first step to making a product available to the clinical population is often obtaining patent protection, resulting in litigation around ADCs.
Members of Congress Call for DOJ to Investigate Possible Antitrust Violations in Oil Industry
On May 30, 23 Senators signed a letter to the Attorney General, calling on the U.S. Department of Justice’s Antitrust Division to “use every tool” to investigate the oil industry for potential violations of the Sherman Antitrust Act, including price fixing.
2024 Health Care & Life Sciences Top Trends
Foley & Lardner’s 2024 Health Care & Life Sciences Top Trends publication unpacks fast-moving developments to help your business.
Foley Attorneys Unpack DOJ's New Whistleblower Rewards Program, Implications for Health Providers
The authors assess the U.S. Department of Justice's new whistleblower incentive and rewards program, offering detail on its basic facets and potential implications for the health care industry.
FDA Allows Pharmacists to Prescribe the COVID-19 Antiviral Paxlovid
The FDA revised its emergency use authorization (EUA) for the COVID-19 antiviral treatment Paxlovid to allow prescribing by pharmacists.